Loading...
•
Mar 31, 2020
Abbott Q1 2020 Earnings Report
Abbott's Q1 2020 financial results were announced, reflecting the impact of the COVID-19 pandemic and the company's response.
Key Takeaways
Abbott's Q1 2020 worldwide sales reached $7.7 billion, a 2.5% increase on a reported basis and a 4.3% increase on an organic basis. The company launched three new COVID-19 tests and is suspending its previously announced annual guidance for 2020 due to uncertainties related to the pandemic.
Worldwide sales increased by 2.5% on a reported basis and 4.3% on an organic basis.
Nutrition sales increased 6.3% on a reported basis and 7.3% on an organic basis, positively impacted by increased demand in late March.
Diagnostics sales decreased 0.8% on a reported basis but increased 0.7% on an organic basis, with Core Laboratory Diagnostics negatively impacted by lower routine testing volumes.
Abbott is suspending its previously announced annual guidance for 2020 due to uncertainties regarding the duration and impact of the coronavirus (COVID-19) pandemic.
Forward Guidance
Due to uncertainties regarding the duration and impact of the coronavirus (COVID-19) pandemic, Abbott is suspending its previously announced annual guidance for 2020.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...